CN Patent

CN110831582B — 药物组合物

Assigned to Novartis AG · Expires 2023-08-11 · 3y expired

What this patent protects

本发明涉及包含作为活性成分的N‑{3‑[5‑(2‑氨基‑4‑嘧啶基)‑2‑(1,1‑二甲基乙基)‑1,3‑噻唑‑4‑基]‑2‑氟苯基}‑2,6‑二氟苯磺酰胺甲磺酸盐的分散片、所述分散片的制备方法、及所述分散片的使用方法。

USPTO Abstract

本发明涉及包含作为活性成分的N‑{3‑[5‑(2‑氨基‑4‑嘧啶基)‑2‑(1,1‑二甲基乙基)‑1,3‑噻唑‑4‑基]‑2‑氟苯基}‑2,6‑二氟苯磺酰胺甲磺酸盐的分散片、所述分散片的制备方法、及所述分散片的使用方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN110831582B
Jurisdiction
CN
Classification
—
Expires
2023-08-11
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.